Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tvardi Therapeutics, Inc. (TVRD)
Company Research
Source: GlobeNewswire
HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmonary function, further supporting the impact of TTI-101 on the inhibition of STAT3 in fibrosis and inflammation. For additional information regarding today’s Phase 2 REVERT IPF data announcement, please visit here. Details are as follows: 44th Annual J.P. Morgan Healthcare ConferenceFormat: Compan
Show less
Read more
Impact Snapshot
Event Time:
TVRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVRD alerts
High impacting Tvardi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVRD
News
- Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights [Yahoo! Finance]Yahoo! Finance
- Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsGlobeNewswire
- Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVRD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVRD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
TVRD
Earnings
- 11/13/25 - Beat
TVRD
Sec Filings
- 1/16/26 - Form 8-K
- 12/18/25 - Form 8-K
- 12/18/25 - Form 4
- TVRD's page on the SEC website